- Raw materials
- Cardiac stimulants
- Dobutamine
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Dobutamine API Manufacturers & Suppliers
7 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Employees: 19
All certificates
Employees: 10
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Dobutamine | CAS No: 34368-04-2 | GMP-certified suppliers
A medication that provides short-term inotropic support for patients with cardiac decompensation due to reduced myocardial contractility from heart disease or cardiac surgery.
Therapeutic categories
Primary indications
- Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
Product Snapshot
- Dobutamine is a parenteral small molecule formulated as injectable solutions and concentrates
- It is primarily used for short-term inotropic support in patients with cardiac decompensation
- Dobutamine holds approved regulatory status in key markets including the US and Canada
Clinical Overview
Pharmacologically, dobutamine acts as a direct-acting inotropic agent by selectively stimulating beta-1 adrenergic receptors located in cardiac tissue. This receptor activation leads to increased myocardial contractility and stroke volume, thereby enhancing cardiac output without significantly increasing heart rate or systemic vascular resistance. Unlike dopamine, dobutamine does not induce endogenous norepinephrine release, resulting in comparatively mild chronotropic and hypertensive effects. Its activity on beta-2 and alpha-adrenergic receptors is minimal, contributing to a reduced risk of vasoconstriction and tachycardia.
Key ADME parameters indicate that dobutamine is primarily metabolized by catechol-O-methyltransferase (COMT) and eliminated mainly through renal excretion. The compound's rapid onset of action and short half-life facilitate titratable intravenous administration in acute care settings.
Safety considerations include monitoring for arrhythmias, as beta-1 stimulation can provoke arrhythmogenic responses. Additionally, caution is advised in patients with idiopathic hypertrophic subaortic stenosis or those with outflow obstruction, where increased contractility may be detrimental. As with other sympathomimetic agents, vigilance for hypertension and tachycardia is warranted, although these effects are generally less pronounced with dobutamine.
Dobutamine is available under various brand names internationally and is widely employed in critical care and cardiac intensive care units for hemodynamic support.
When procuring dobutamine API for pharmaceutical formulation, stringent quality control measures should be observed, including verification of chemical identity, purity, residual solvents, and stability. Compliance with relevant pharmacopeial standards and regulatory guidelines is essential to ensure consistent efficacy and safety in parenteral drug products.
Identification & chemistry
| Generic name | Dobutamine |
|---|---|
| Molecule type | Small molecule |
| CAS | 34368-04-2 |
| UNII | 3S12J47372 |
| DrugBank ID | DB00841 |
Pharmacology
| Summary | Dobutamine is a direct-acting inotropic agent that selectively stimulates beta-1 adrenergic receptors in the heart to enhance myocardial contractility and increase cardiac output. It exhibits minimal activity at beta-2 and alpha-1 receptors and does not induce endogenous norepinephrine release. This pharmacologic profile supports its use in providing short-term inotropic support in cases of cardiac decompensation associated with impaired contractile function. |
|---|---|
| Mechanism of action | Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. |
| Pharmacodynamics | Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Alpha-1 adrenergic receptors | Humans | agonist |
| Beta-1 adrenergic receptor | Humans | agonist |
| Beta-2 adrenergic receptor | Humans | agonist |
ADME / PK
| Half-life | 2 minutes |
|---|---|
| Route of elimination | In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. |
Formulation & handling
- Dobutamine is formulated exclusively for intravenous and parenteral administration due to its poor oral bioavailability.
- As a small molecule catecholamine, dobutamine requires protection from oxidation and light exposure during storage and handling.
- Low water solubility necessitates formulation in aqueous solutions or concentrates suitable for parenteral infusion.
Regulatory status
| Lifecycle | The API is approaching patent expiry in the US and Canada, leading to increased availability of generic versions and a transition towards a mature market phase characterized by competitive pricing and broader access. |
|---|
| Markets | US, Canada |
|---|
Supply Chain
| Supply chain summary | Dobutamine is supplied by multiple manufacturers, including several originator and generic companies, indicating a mature manufacturing landscape with established production capabilities. Its branded products primarily serve the US and Canadian markets, with no mention of European presence. Given the diverse range of suppliers, the product is subject to existing generic competition following patent expiry. |
|---|
Dobutamine is a type of Cardiac stimulants
Cardiac stimulants are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of cardiac disorders. These medications are designed to enhance the functioning of the heart by stimulating its electrical impulses and increasing its contractility.
Cardiac stimulants work by targeting specific receptors in the heart, promoting the release of neurotransmitters such as norepinephrine and epinephrine. These neurotransmitters bind to adrenergic receptors, leading to an increased heart rate and force of contraction, which helps improve cardiac output.
One commonly used cardiac stimulant API is Dobutamine. Dobutamine acts primarily on beta-1 adrenergic receptors in the heart, increasing the strength of cardiac contractions while minimizing the impact on heart rate. This makes it a valuable medication in cases of acute heart failure or during cardiac stress testing.
Another well-known cardiac stimulant API is Isoproterenol. Isoproterenol acts on both beta-1 and beta-2 adrenergic receptors, resulting in increased heart rate, contractility, and relaxation of the smooth muscles in the bronchi. It is commonly used in the treatment of bradycardia, heart block, and certain types of asthma.
Cardiac stimulant APIs play a vital role in cardiovascular medicine and are often used in emergency situations or as temporary measures to improve heart function. However, it is important to note that their use requires careful monitoring and should be administered under medical supervision due to potential side effects such as increased blood pressure, arrhythmias, and myocardial ischemia.
In conclusion, cardiac stimulant APIs are a critical category of pharmaceutical ingredients used to enhance heart function. Medications like Dobutamine and Isoproterenol act on specific receptors in the heart, leading to increased contractility and heart rate. While these medications provide important therapeutic benefits, their use should be closely monitored by medical professionals due to potential side effects.
Dobutamine API manufacturers & distributors
Compare qualified Dobutamine API suppliers worldwide. We currently have 7 companies offering Dobutamine API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Bioindustria | Producer | Italy | Italy | CEP, CoA, FDA, GMP | 12 products |
| GVK Biosciences Pvt Ltd | Producer | India | India | CEP, CoA, FDA, GMP, WC | 10 products |
| Katsura Chemical | Producer | Japan | Japan | CoA, JDMF | 7 products |
| Recordati S.p.A. | Producer | Italy | Italy | CEP, CoA, GMP, USDMF | 18 products |
| SETV Global | Producer | India | India | CoA, FDA, GMP | 515 products |
| Sun Pharma | Producer | India | India | CoA, GMP, WC | 219 products |
| Tenatra Exports Private L... | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, MSDS | 263 products |
When sending a request, specify which Dobutamine API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Dobutamine API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
